06Nov/13

SDSU receives $8.5M grant for heart research – San Diego Source (subscription)


10News

SDSU receives $8.5M grant for heart research
San Diego Source (subscription)
of the program is to develop new therapeutic strategies using stem cell-based treatment to regenerate the heart. Advancing these strategies is critical — as current alternatives are costly and include painful transplant surgery for severe heart
SDSU receives $8.5M for heart researchPhys.Org

all 4 news articles »

06Nov/13

Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury … – 4-traders (press release)

Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury
4-traders (press release)
‘Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney

and more »

06Nov/13

Why Charity is Right John Lorigan responds to the article "Why Charity is Wrong". – The University Times


The University Times

Why Charity is Right John Lorigan responds to the article “Why Charity is Wrong”.
The University Times
In the article, “Why charity is wrong”, the author mentions several things, including the VDP, global injustice, and how our political system is questionable. The fact that the world is unjust is To run with the biological metaphor, what about

06Nov/13

Research and Markets: Therapy Class Overview : Rituximab Biosimilar … – Business Wire (press release)

Research and Markets: Therapy Class Overview : Rituximab Biosimilar
Business Wire (press release)
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several

and more »

06Nov/13

Research and Markets: Therapy Class Overview : Rituximab Biosimilar … – 4-traders (press release)

Research and Markets: Therapy Class Overview : Rituximab Biosimilar
4-traders (press release)
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several

and more »